[非肌层浸润性膀胱癌的治疗研究：欧洲泌尿外科学会（AUO）AB 40/11研究中，槲寄生提取物膀胱灌注治疗浅表性膀胱癌的III期疗效试验（TIM）] - Suppr | 超能文献

[Study for the treatment of nonmuscle invasive bladder cancer : A phase III efficacy trial for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) - AB 40/11 of the AUO].

作者信息

Rexer H

机构信息

MeckEvidence, Seestr. 11, 17252, Schwarz, Deutschland.

出版信息

Urologe A. 2016 Jul;55(7):963-5. doi: 10.1007/s00120-016-0135-0.

DOI:10.1007/s00120-016-0135-0

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Study for the treatment of nonmuscle invasive bladder cancer : A phase III efficacy trial for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) - AB 40/11 of the AUO].[非肌层浸润性膀胱癌的治疗研究：欧洲泌尿外科学会（AUO）AB 40/11研究中，槲寄生提取物膀胱灌注治疗浅表性膀胱癌的III期疗效试验（TIM）]

Urologe A. 2016 Jul;55(7):963-5. doi: 10.1007/s00120-016-0135-0.

2

[Study on the treatment of nonmuscle invasive bladder cancer: A phase III efficacy study for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) AB 40/11 of the AUO].非肌层浸润性膀胱癌的治疗研究：AUO的AB 40/11（槲寄生提取物膀胱灌注治疗浅表性膀胱癌的III期疗效研究（TIM））

Urologe A. 2015 Mar;54(3):406-8. doi: 10.1007/s00120-015-3781-8.

3

Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study.槲寄生植物提取物治疗非肌层浸润性膀胱癌患者：一项Ib/IIa期单组剂量递增研究的结果

J Urol. 2015 Oct;194(4):939-43. doi: 10.1016/j.juro.2015.04.073. Epub 2015 Apr 22.

4

Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.采用标准化槲寄生提取物进行膀胱内辅助治疗以预防浅表性膀胱癌复发。

Anticancer Res. 2005 Nov-Dec;25(6C):4733-6.

5

Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.用标准化槲寄生提取物对浅表性膀胱癌进行膀胱内辅助治疗。

J Urol. 2005 Jul;174(1):76-9. doi: 10.1097/01.ju.0000163261.08619.d0.

6

[A study of non-muscle-invasive bladder cancer therapy : Treatment of high-grade non-muscle-invasive urothelial carcinoma of the bladder with the standard number and dosage of intravesical BCG instillations versus a reduced number intravesical BCG instillations at the standard dosage: A European Association of Urology Research Foundation randomized phase 3 study - NIMBUS - AB 37/10 of the AUO].

Urologe A. 2016 Apr;55(4):528-31. doi: 10.1007/s00120-016-0051-3.

7

[Study on the therapy of nonmuscle-invasive bladder cancer: treatment of nonmuscle-invasive high-grade urothelial cancer of the bladder with the standard number and dosage of intravesical BCG instillations versus a reduced number of intravesical BCG instillations in the standard dosage: a randomized phase 3 study of the European Association of Urology Research Foundation (NIMBUS - AB 37/10 of the AUO)].

Urologe A. 2014 Jun;53(6):890-2. doi: 10.1007/s00120-014-3458-8.

8

[First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].局部晚期或转移性尿路上皮癌的一线治疗：一项关于辅助性纳武单抗治疗与安慰剂对比治疗侵袭性高危尿路上皮癌患者的随机双盲III期多中心研究（CheckMate 274）-AUO的AB 58/17

Urologe A. 2017 Oct;56(10):1331-1332. doi: 10.1007/s00120-017-0480-7.

9

Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.非肌层浸润性膀胱癌患者经尿道切除术后立即灌注阿帕喹酮的安全性和副作用

J Urol. 2008 Jul;180(1):116-20. doi: 10.1016/j.juro.2008.03.031. Epub 2008 May 15.

10

In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.体内评价黏附性纳米粒多西紫杉醇用于非肌肉浸润性膀胱癌的膀胱内治疗。

Clin Cancer Res. 2011 May 1;17(9):2788-98. doi: 10.1158/1078-0432.CCR-10-2981. Epub 2011 Feb 28.

引用本文的文献

1

(L.) in experimental animal tumors: A meta-analysis.（L.）在实验动物肿瘤中的一项荟萃分析。

Exp Ther Med. 2017 Jun;13(6):2723-2740. doi: 10.3892/etm.2017.4372. Epub 2017 Apr 21.